Lexaria Ev To Operating Cash Flow from 2010 to 2024

LEXXW Stock  USD 0.78  0.03  4.00%   
Lexaria Bioscience EV To Operating Cash Flow yearly trend continues to be fairly stable with very little volatility. EV To Operating Cash Flow is likely to outpace its year average in 2024. EV To Operating Cash Flow is a valuation metric comparing Lexaria Bioscience's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. View All Fundamentals
 
EV To Operating Cash Flow  
First Reported
2010-12-31
Previous Quarter
(8.48)
Current Value
362.55041533
Quarterly Volatility
94.74076966
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 125.2 K or Other Operating Expenses of 3.2 M, as well as many indicators such as Price To Sales Ratio of 105, Dividend Yield of 0.0 or PTB Ratio of 54.87. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Ev To Operating Cash Flow Growth Pattern

Below is the plot of the Ev To Operating Cash Flow of Lexaria Bioscience Corp over the last few years. It is a valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. Lexaria Bioscience's EV To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
Ev To Operating Cash Flow10 Years Trend
Slightly volatile
   Ev To Operating Cash Flow   
       Timeline  

Lexaria Ev To Operating Cash Flow Regression Statistics

Arithmetic Mean20.17
Geometric Mean5.15
Coefficient Of Variation469.66
Mean Deviation45.65
Median(3.78)
Standard Deviation94.74
Sample Variance8,976
Range372
R-Value0.43
Mean Square Error7,857
R-Squared0.19
Significance0.11
Slope9.17
Total Sum of Squares125,661

Lexaria Ev To Operating Cash Flow History

2024 362.55
2023 -8.48
2022 -0.98
2021 -2.39
2020 -4.13
2019 -4.24
2018 -3.44

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Ev To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Operating Cash Flow(8.48) 362.55 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.